Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment

Wright, J. L.; Levy, R. D.; Churg, A.
July 2005
Thorax;Jul2005, Vol. 60 Issue 7, p605
Academic Journal
journal article
The development of pulmonary hypertension is a poor prognostic sign in patients with chronic obstructive pulmonary disease (COPD), affecting both mortality and quality of life. Although pulmonary hypertension in COPD is traditionally viewed as a result of emphysematous destruction of the vascular bed and/or hypoxia, recent studies indicate that neither of these factors correlates very well with pulmonary artery pressures. New human and animal experimental data are beginning to show that pulmonary hypertension in this setting is probably a result of the direct effect of tobacco smoke on the intrapulmonary vessels with abnormal production of mediators that control vasoconstriction, vasodilatation, and vascular cell proliferation, ultimately leading to aberrant vascular remodelling and aberrant vascular physiology. These changes are in many ways similar to those seen in other forms of pulmonary hypertension and suggest that the treatments used for primary pulmonary hypertension may be beneficial in patients with COPD.


Related Articles

  • Chronic bronchitis and emphysema. Tattersfield, Anne E. // British Medical Journal;4/29/1978, Vol. 1 Issue 6120, p1123 

    Any disease that affects one million people in the United Kingdom and causes 30 000 deaths a year must be so familiar to all practising doctors that articles on treatment and management might be considered superfluous, particularly when the effects of treatment are unlikely to be dramatic. No...

  • Ambulatory pulmonary artery pressure monitoring during sleep and exercise in normal individuals and patients with COPD. Raeside, D. A.; Brown, A.; Patel, K. R.; Welsh, D.; Peacock, A. J. // Thorax;Dec2002, Vol. 57 Issue 12, p1050 

    Background: Pulmonary hypertension is a common complication of chronic obstructive airways disease (COPD) and its presence implies a poor prognosis. However, it is difficult to measure and its specific contribution to symptoms is difficult to quantify. A micromanometer tipped pulmonary artery...

  • Right Heart Structural Changes Are Independently Associated with Exercise Capacity in Non-Severe COPD. Cuttica, Michael J.; Shah, Sanjiv J.; Rosenberg, Sharon R.; Orr, Randy; Beussink, Lauren; Dematte, Jane E.; Smith, Lewis J.; Kalhan, Ravi // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Background Pulmonary hypertension (PH) occurs frequently and results in functional limitation in advanced COPD. Data regarding the functional consequence of PH in less severe COPD are limited. Whether echocardiographic evidence of right sided heart pathology is associated with functional...

  • Mechanisms of development of chronic obstructive pulmonary disease-associated pulmonary hypertension. Barberà, Joan Albert // Pulmonary Circulation;Jan-Mar2013, Vol. 3 Issue 1, p160 

    Pulmonary hypertension is a prevalent complication of chronic obstructive pulmonary disease (COPD) that is associated with poor prognosis. Although pulmonary hypertension is usually diagnosed in patients with advanced disease, changes in pulmonary vessels are already apparent at early disease...

  • Drawing Impairment Predicts Mortality in Severe COPD.  // Cardiopulmonary Physical Therapy Journal (American Physical Ther;Mar2007, Vol. 18 Issue 1, p26 

    The article summarizes and comments on the paper "Drawing Impairment Predicts Mortality in Severe COPD," by R. Antonelli-Incalzi and colleagues, published in a 2006 issue of the "Journal of Applied Physiology." The data indicates that drawing impairment is a risk factor for mortality and might...

  • Perlecan heparan sulfate in hypoxia-induced pulmonary vascular remodeling. Chang, Y.; Tannenberg, P.; Tseng, C.; Tran, P.; Hedin, U.; Tran-Lundmark, K. // Proceedings of the Physiological Society;2013, p843P 

    Chronic hypoxia can induce pulmonary vascular smooth muscle cell (SMC) proliferation, which contributes to blood vessel constriction and lumen narrowing, leading to pulmonary hypertension. Perlecan is the major heparan sulfate proteoglycan in the basement membrane. The heparan sulfate chains of...

  • Cellular responses to hypoxia after renal segmental infarction. Rosenberger, Christian; Griethe, Wanja; Gruber, Gertrud; Wiesener, Michael; Frei, Ulrich; Bachmann, Sebastian; Eckardt, Kai-Uwe // Kidney International;Sep2003, Vol. 64 Issue 3, p874 

    Background: Hypoxia is believed to play an important role in the pathogenesis of acute and chronic kidney disease. However, the impact of low oxygen tensions on cellular functions in the kidney and potential adaptive responses are poorly understood. Methods: In order to...

  • Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Wanstall, Janet C.; Gambino, Agatha; Jeffery, Trina K.; Cahill, Marian M.; Bellomo, Daniela; Hayward, Nicholas K.; Kay, Graham F. // Cardiovascular Research;Sep2002, Vol. 55 Issue 2, p361 

    Objective: To test the hypothesis that Vegf-B contributes to the pulmonary vascular remodelling, and the associated pulmonary hypertension, induced by exposure of mice to chronic hypoxia. Methods: Right ventricular systolic pressure, the ratio of right ventricle/[left...

  • Chronic Hypoxia- and Monocrotaline-Induced Elevation of Hypoxia-Inducible Factor-1α Levels and Pulmonary Hypertension. Yih-Loong Lai; Tai Chung Law // Journal of Biomedical Science;May/Jun2004, Vol. 11 Issue 3, p315 

    A close relationship exists between hypoxia-inducible factor (HIF)-1α and pulmonary hypertension. The present study was carried out to explore if there are temporal alterations in HIF-1α levels during prolonged hypoxia and after monocrotaline (MCT) treatment. First, young Wistar rats were...


Read the Article


Sign out of this library

Other Topics